Publications by authors named "William D Figg"

100Publications

Drug-drug Interactions in Patients with HIV and Cancer in Sub-Saharan Africa.

AIDS Rev 2020 Oct 26;23(3). Epub 2020 Oct 26.

Molecular Pharmacology Section, National Cancer Institute, National Institute of Health, Bethesda, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.24875/AIDSRev.20000005DOI Listing
October 2020

BETting on next-generation bromodomain inhibitors.

Am J Clin Exp Urol 2020 15;8(4):129-132. Epub 2020 Aug 15.

Molecular Pharmacology Section, Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health Bethesda, MD, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7486540PMC
August 2020

Population pharmacokinetic analysis of nanoparticle-bound and free camptothecin after administration of NLG207 in adults with advanced solid tumors.

Cancer Chemother Pharmacol 2020 Oct 8;86(4):475-486. Epub 2020 Sep 8.

Clinical Pharmacology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Building 10/Room 5A03, Bethesda, MD, 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-020-04134-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7515962PMC
October 2020

Exploiting defects in homologous recombination repair for metastatic, castration-resistant prostate cancer.

Cancer Biol Ther 2020 Oct 26;21(10):884-887. Epub 2020 Aug 26.

Genitourinary Malignancies Branch, National Institutes of Health , Bethesda, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/15384047.2020.1809913DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7583699PMC
October 2020

Examining HSD3B1 as a possible biomarker to detect prostate cancer patients who are likely to progress on ADT.

Cancer Biol Ther 2020 Sep 13;21(9):782-784. Epub 2020 Aug 13.

Clinical Pharmacology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health , Bethesda, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/15384047.2020.1796195DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7515525PMC
September 2020

PARP Inhibitors and Prostate Cancer: To Infinity and Beyond BRCA.

Oncologist 2020 Aug 13. Epub 2020 Aug 13.

Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2020-0697DOI Listing
August 2020

Role of cereblon in angiogenesis and in mediating the antiangiogenic activity of immunomodulatory drugs.

FASEB J 2020 Jul 17. Epub 2020 Jul 17.

Molecular Pharmacology Section, Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1096/fj.201903060RRDOI Listing
July 2020

Are sex discordant outcomes in COVID-19 related to sex hormones?

Semin Oncol 2020 10 17;47(5):335-340. Epub 2020 Jun 17.

Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2020.06.002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7298487PMC
October 2020

COVID-19 Clinical Diagnostics and Testing Technology.

Pharmacotherapy 2020 08;40(8):857-868

Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/phar.2439DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7361586PMC
August 2020

Slow-, Tight-Binding Inhibition of CYP17A1 by Abiraterone Redefines Its Kinetic Selectivity and Dosing Regimen.

J Pharmacol Exp Ther 2020 09 17;374(3):438-451. Epub 2020 Jun 17.

Department of Pharmacy, Faculty of Science (E.J.Y.C., R.W.Y.N., H.T.T., C.L.L.C., E.C.Y.C.) and Department of Biological Sciences (H.F.), National University of Singapore, Singapore, Singapore; Department of Clinical Pharmacology and Flinders Centre for Innovation in Cancer, College of Medicine and Public Health, Flinders University, Adelaide, Australia (P.C.N., J.O.M.); Bioinformatics Institute, Biotransformation Innovation Platform (BioTrans) (F.L.) and Bioinformatics Institute (H.F.), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore; Department of Surgery, National University Health System, Singapore, Singapore (E.C., K.E.); Department of Urology, National University Hospital, Singapore, Singapore (E.C., K.E.); Centre for Computational Biology, DUKE-NUS Medical School, Singapore, Singapore (H.F.); The University of Chicago, Chicago, Illinois (R.Z.S.); National Cancer Institute, Rockville, Maryland (C.J.P., W.D.F.); and National University Cancer Institute, Singapore (NCIS), NUH Medical Centre (NUHMC), Singapore, Singapore (E.C.Y.C.)

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/jpet.120.265868DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7469252PMC
September 2020

TMPRSS2: Potential Biomarker for COVID-19 Outcomes.

J Clin Pharmacol 2020 07 21;60(7):801-807. Epub 2020 May 21.

Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcph.1641DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7280622PMC
July 2020

Opportunities for using in silico-based extended dosing regimens for monoclonal antibody immune checkpoint inhibitors.

Br J Clin Pharmacol 2020 May 18. Epub 2020 May 18.

Department of Medicine, Center for Personalized Therapeutics, and Comprehensive Cancer Center, The University of Chicago, Chicago, IL, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bcp.14369DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7444775PMC
May 2020

Phase 2 Study of Seviteronel (INO-464) in Patients With Metastatic Castration-Resistant Prostate Cancer After Enzalutamide Treatment.

Clin Genitourin Cancer 2020 08 29;18(4):258-267.e1. Epub 2020 Mar 29.

Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD; Clinical Pharmacology Program, Office of the Clinical Director, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2019.11.002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7415516PMC
August 2020

Plasma and cerebrospinal fluid pharmacokinetics of the DNA methyltransferase inhibitor, 5-azacytidine, alone and with inulin, in nonhuman primate models.

Neurooncol Adv 2020 Jan-Dec;2(1):vdaa005. Epub 2020 Jan 1.

Pediatric Neuro-Oncology Section, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/noajnl/vdaa005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7146732PMC
January 2020

Cerebrospinal fluid penetration of the colony-stimulating factor-1 receptor (CSF-1R) inhibitor, pexidartinib.

Cancer Chemother Pharmacol 2020 05 18;85(5):1003-1007. Epub 2020 Apr 18.

Pediatric Oncology Branch, National Cancer Institute, NIH, Bethesda, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-020-04071-7DOI Listing
May 2020

Selumetinib in Children with Inoperable Plexiform Neurofibromas.

N Engl J Med 2020 04 18;382(15):1430-1442. Epub 2020 Mar 18.

From the Pediatric Oncology Branch (A.M.G., P.L.W., E.D., P.W., S.M., M.C.R., D.C.P., A.C., J.T., O.K., J.G., B.C.W.) and the Clinical Pharmacology Program (C.J.P., W.D.F.), Center for Cancer Research, National Cancer Institute, and the Rehabilitation Medicine Department, Clinical Center (S.M.P), National Institutes of Health, Bethesda, the Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick (A.B., K.H.), the Cancer Therapy Evaluation Program (M.S., L.A.D.) and the Biostatistics and Data Management Section, Center for Cancer Research (S.M.S., D.J.V.), National Cancer Institute, National Institutes of Health, Shady Grove, and Johns Hopkins University School of Medicine, Baltimore (J.O.B.) - all in Maryland; Children's Hospital of Philadelphia, Philadelphia (M.J.F., A.C.S.); Cincinnati Children's Hospital, Cincinnati (B.W.); Children's National Hospital, Washington, DC (A.K., M.B.); and Indiana University School of Medicine, Indianapolis (D.W.C., C.Z.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1912735DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7305659PMC
April 2020

Targeting Pancreatic Cancer Cells and Stellate Cells Using Designer Nanotherapeutics in vitro.

Int J Nanomedicine 2020 13;15:991-1003. Epub 2020 Feb 13.

Department of Pathology, The University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/IJN.S234112DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7025663PMC
June 2020

Stem cell clinics: risk of proliferation.

Lancet Oncol 2020 02;21(2):205-206

Clinical Pharmacology Program, Office of the Clinical Director, National Cancer Institute, Bethesda, MD 20892, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(19)30787-9DOI Listing
February 2020

Measurement of NLG207 (formerly CRLX101) nanoparticle-bound and released camptothecin in human plasma.

J Pharm Biomed Anal 2020 Mar 27;181:113073. Epub 2019 Dec 27.

Clinical Pharmacology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA; Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jpba.2019.113073DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7068816PMC
March 2020

Androgen receptor splice variant 7 (AR-V7) and AR full-length (AR-FL) as predictive biomarkers of therapeutic resistance: partners in crime?

BJU Int 2019 10 20;124(4):549-550. Epub 2019 Sep 20.

Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bju.14869DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6943979PMC
October 2019

Characterizing the pharmacokinetics of panobinostat in a non-human primate model for the treatment of diffuse intrinsic pontine glioma.

Cancer Chemother Pharmacol 2020 04 1;85(4):827-830. Epub 2020 Jan 1.

Pediatric Oncology Branch, National Cancer Institute, NIH, Bethesda, MD, 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-019-04021-yDOI Listing
April 2020

Local and Systemic Antitumor Effects of Photo-activatable Paclitaxel Prodrug on Rat Breast Tumor Models.

Photochem Photobiol 2020 05 9;96(3):668-679. Epub 2020 Mar 9.

Department of Pharmaceutical Sciences, University at Buffalo, State University of New York, Buffalo, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/php.13202DOI Listing
May 2020

Low Doses of CPS49 and Flavopiridol Combination as Potential Treatment for Advanced Prostate Cancer.

Curr Pharm Biotechnol 2019;20(12):1072

Laboratorio de Oncologia Molecular y Nuevos Blancos Terapeuticos, Instituto de Biologia y Medicina Experimental (IBYME-CONICET), Buenos Aires, Argentina.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/138920102012190919103433DOI Listing
January 2019

Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomide.

Sci Rep 2019 10 16;9(1):14884. Epub 2019 Oct 16.

Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-019-51446-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6795854PMC
October 2019

Combination treatment in metastatic castration-resistant prostate cancer: can we safely boost efficacy by adding radium-223?

Cancer Biol Ther 2020 18;21(1):1-3. Epub 2019 Sep 18.

Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/15384047.2019.1665395DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7012084PMC
July 2020

Antibody-drug conjugates for cancer.

Lancet 2019 08;394(10200):793-804

Molecular Pharmacology Section, Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(19)31774-XDOI Listing
August 2019

A population pharmacokinetic analysis of the oral CYP17 lyase and androgen receptor inhibitor seviteronel in patients with advanced/metastatic castration-resistant prostate cancer or breast cancer.

Cancer Chemother Pharmacol 2019 10 31;84(4):759-770. Epub 2019 Jul 31.

Clinical Pharmacology Program, CCR, National Cancer Institute, NIH, 9000 Rockville Pike, Building 10, Room 5A01, Bethesda, MD, 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-019-03908-0DOI Listing
October 2019

PBPK modeling-based optimization of site-specific chemo-photodynamic therapy with far-red light-activatable paclitaxel prodrug.

J Control Release 2019 08 9;308:86-97. Epub 2019 Jul 9.

Department of Pharmaceutical Sciences, College of Pharmacy, University of Oklahoma Health Sciences Center, Oklahoma City 73117, OK, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01683659193039
Publisher Site
http://dx.doi.org/10.1016/j.jconrel.2019.07.010DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6710169PMC
August 2019

How do you take your coffee?

Lancet Oncol 2019 Jul;20(7):913-914

Clinical Pharmacology Program, Office of the Clinical Director, National Cancer Institute, Bethesda, MD 20892, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(19)30387-0DOI Listing
July 2019

Severe Hepatotoxicity of Mithramycin Therapy Caused by Altered Expression of Hepatocellular Bile Transporters.

Mol Pharmacol 2019 08 7;96(2):158-167. Epub 2019 Jun 7.

Clinical Pharmacology Program (T.M.S., C.J.P., W.D.F.), Molecular Pharmacology Section (P.A.H., R.J.H., E.M.M., R.H.B., J.D.S., A.M.L., W.D.F.), Biostatistics and Data Management Section (M.Z., J.A.H., D.V.), Pediatric Oncology Branch (P.G., J.G., B.C.W.), Thoracic Surgery Branch, Center for Cancer Research, National Cancer Institute (D.S.S.), and Translational Hepatology Section (T.H.), Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland; and BioIVT, ADME-Tox Division, Durham, North Carolina (J.P.J., K.R.B.)

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/mol.118.114827DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6608607PMC
August 2019

Detectible mosaic truncating PPM1D mutations, age and breast cancer risk.

J Hum Genet 2019 Jun 8;64(6):545-550. Epub 2019 Mar 8.

Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s10038-019-0589-1DOI Listing
June 2019

Reproducibility of pharmacogenetics findings for paclitaxel in a heterogeneous population of patients with lung cancer.

PLoS One 2019 28;14(2):e0212097. Epub 2019 Feb 28.

Clinical Pharmacology Program, Office of the Clinical Director, National Cancer Institute, Bethesda, Maryland, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0212097PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394902PMC
November 2019

Insulin potentiation therapy for cancer?

Lancet Oncol 2019 02;20(2):191-192

Clinical Pharmacology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(19)30003-8DOI Listing
February 2019

The effect of anti-CTLA4 treatment on peripheral and intra-tumoral T cells in patients with hepatocellular carcinoma.

Cancer Immunol Immunother 2019 Apr 28;68(4):599-608. Epub 2019 Jan 28.

Gastrointestinal Malignancies Section, Thoracic and GI Oncology Branch, Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Building 10, Room 3B43, Bethesda, MD, 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-019-02299-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6662600PMC
April 2019

Alam K et al. (2018) Drug Metabolism Letters; 12, 24-32.

Drug Metab Lett 2018 ;12(2):153

Clinical Pharmacology Program, Office of the Clinical Director, and the Molecular Pharmacology Section, Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, MD, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1872312812999180724145725DOI Listing
February 2019

Synthesis, Structural Characterization, and Antiangiogenic Activity of Polyfluorinated Benzamides.

ChemMedChem 2018 10 6;13(19):2080-2089. Epub 2018 Sep 6.

Pharmaceutical Institute, Pharmaceutical Chemistry I, University of Bonn, An der Immenburg 4, 53121, Bonn, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cmdc.201800263DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6631341PMC
October 2018

Preclinical Evaluation of Discorhabdins in Antiangiogenic and Antitumor Models.

Mar Drugs 2018 Jul 19;16(7). Epub 2018 Jul 19.

Molecular Pharmacology Section, Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/md16070241DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6071056PMC
July 2018

Precision medicine applications in prostate cancer.

Ther Adv Med Oncol 2018 18;10:1758835918776920. Epub 2018 Jun 18.

Clinical Pharmacology Program, Office of the Clinical Director, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Rockville Pike, Bldg 10/Room 5A01, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1758835918776920DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6024288PMC
June 2018

Antineoplastons: when is enough enough?

Authors:
William D Figg

Lancet Oncol 2018 Jun 1;19(6):733-734. Epub 2018 Jun 1.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(18)30338-3DOI Listing
June 2018

Tissue preservation with mass spectroscopic analysis: Implications for cancer diagnostics.

Cancer Biol Ther 2018 31;19(11):953-955. Epub 2018 May 31.

a Clinical Pharmacology Program , National Cancer Institute , Bethesda , MD.

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/15384047.2018.1
Publisher Site
http://dx.doi.org/10.1080/15384047.2018.1456610DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6301822PMC
May 2018

Molecular drivers of metastatic castrate-resistant prostate cancer: New roads to resistance.

Cancer Biol Ther 2018 14;19(10):869-870. Epub 2018 May 14.

a Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health , Bethesda , MD , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/15384047.2018.1449618DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6300349PMC
May 2019

Novel Fluoroindenoisoquinoline Non-Camptothecin Topoisomerase I Inhibitors.

Mol Cancer Ther 2018 08 10;17(8):1694-1704. Epub 2018 May 10.

Developmental Therapeutics Branch & Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland.

View Article

Download full-text PDF

Source
http://mct.aacrjournals.org/lookup/doi/10.1158/1535-7163.MCT
Publisher Site
http://dx.doi.org/10.1158/1535-7163.MCT-18-0028DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6072611PMC
August 2018

Revisiting 5α-reductase inhibitors and the risk of prostate cancer.

Nat Rev Urol 2018 Jul;15(7):400-401

Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41585-018-0018-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358277PMC
July 2018

A sensitive and rapid ultra high-performance liquid chromatography with tandem mass spectrometric assay for the simultaneous quantitation of cyclophosphamide and the 4-hydroxycyclophosphamide metabolite in human plasma.

J Chromatogr B Analyt Technol Biomed Life Sci 2018 Jun 10;1086:56-62. Epub 2018 Apr 10.

Clinical Pharmacology Program, National Cancer Institute, Bethesda, MD, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jchromb.2018.04.016DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5927828PMC
June 2018

Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer.

J Clin Oncol 2018 05 28;36(14):1389-1395. Epub 2018 Mar 28.

Russell Z. Szmulewitz, Abiola Ibraheem, Elia Martinez, Mark F. Kozloff, Chadi Nabhan, Theodore Karrison, Walter M. Stadler, and Mark J. Ratain, The University of Chicago, Chicago; Mark F. Kozloff, Ingalls Hospital, Harvey; Paul Fishkin, Illinois Cancer Care, Peoria, IL; Cody J. Peer and William D. Figg, National Cancer Institute, Rockville, MD; Bradley Carthon and R. Donald Harvey, Winship Cancer Institute of Emory University, Atlanta, GA; and Wei Peng Yong and Edmund Chiong, National University Cancer Institute, Singapore, Singapore.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.76.4381
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.76.4381DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5941614PMC
May 2018

Design, synthesis and biological assessment of N-adamantyl, substituted adamantyl and noradamantyl phthalimidines for nitrite, TNF-α and angiogenesis inhibitory activities.

Bioorg Med Chem 2018 05 10;26(8):1547-1559. Epub 2018 Feb 10.

Drug Design & Development Section, Translational Gerontology Branch, Intramural Research Program, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmc.2018.01.032DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5891396PMC
May 2018

Optimized administration of hetIL-15 expands lymphocytes and minimizes toxicity in rhesus macaques.

Cytokine 2018 08 7;108:213-224. Epub 2018 May 7.

Human Retrovirus Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, MD, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cyto.2018.01.011DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6657354PMC
August 2018

The effect of an adenosine A agonist on intra-tumoral concentrations of temozolomide in patients with recurrent glioblastoma.

Fluids Barriers CNS 2018 Jan 15;15(1). Epub 2018 Jan 15.

Brain Cancer Program, Johns Hopkins University, David H. Koch Cancer Research Building II, 1550 Orleans Street, Room 1M16, Baltimore, MD, 21287, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12987-017-0088-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5767971PMC
January 2018

Expanding the use of abiraterone in prostate cancer: Is earlier always better?

Cancer Biol Ther 2018 02 8;19(2):97-100. Epub 2017 Dec 8.

a Clinical Pharmacology Program, Office of the Clinical Director , National Cancer Institute, NIH , Bethesda , MD , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/15384047.2017.1394555DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5790360PMC
February 2018

Exosome is a mechanism of intercellular drug transfer: Application of quantitative pharmacology.

J Control Release 2017 Dec 18;268:147-158. Epub 2017 Oct 18.

Department of Pharmaceutical Sciences, College of Pharmacy, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73117, USA; Institute of Quantitative Systems Pharmacology, Carlsbad, CA 92008, USA; Optimum Therapeutics LLC, Carlsbad, CA 92008, USA; College of Pharmacy, Taipei Medical University, Taipei, Taiwan. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jconrel.2017.10.020DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5722714PMC
December 2017

CPS49-induced neurotoxicity does not cause limb patterning anomalies in developing chicken embryos.

J Anat 2018 04 10;232(4):568-574. Epub 2017 Oct 10.

School of Medicine, Medical Sciences and Nutrition, Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/joa.12712DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5835787PMC
April 2018

Jumping the Barrier: Modeling Drug Penetration across the Blood-Brain Barrier.

Clin Cancer Res 2017 12 10;23(24):7437-7439. Epub 2017 Oct 10.

Clinical Pharmacology Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-17-2741DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5732885PMC
December 2017

Quantitative modeling of the dynamics and intracellular trafficking of far-red light-activatable prodrugs: implications in stimuli-responsive drug delivery system.

J Pharmacokinet Pharmacodyn 2017 Dec 14;44(6):521-536. Epub 2017 Sep 14.

Department of Pharmaceutical Sciences, College of Pharmacy, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73117, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10928-017-9543-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5688019PMC
December 2017

Discussing the predictive, prognostic, and therapeutic value of germline DNA-repair gene mutations in metastatic prostate cancer patients.

Cancer Biol Ther 2017 08 5;18(8):545-546. Epub 2017 Jul 5.

a Molecular Pharmacology Section, Genitourinary Malignancies Branch , National Institutes of Health , Bethesda , MD , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/15384047.2017.1345398DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5653188PMC
August 2017

Population pharmacokinetic analyses of the effect of carboplatin pretreatment on olaparib in recurrent or refractory women's cancers.

Cancer Chemother Pharmacol 2017 Jul 2;80(1):165-175. Epub 2017 Jun 2.

Clinical Pharmacology Program, CCR, National Cancer Institute, NIH, 9000 Rockville Pike, Building 10, Room 5A01, Bethesda, MD, 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-017-3346-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6361113PMC
July 2017

Carfilzomib and lenalidomide response related to VEGF and VEGFR2 germline polymorphisms.

Cancer Chemother Pharmacol 2017 Jul 9;80(1):217-221. Epub 2017 May 9.

Clinical Pharmacology Program, Office of the Clinical Director, National Cancer Institute, 9000 Rockville Pike, Building 10, Rm 5A01, Bethesda, MD, 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-017-3323-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6387687PMC
July 2017

Diagnosis, staging, and risk stratification in prostate cancer: Utilizing diagnostic tools to avoid unnecessary therapies and side effects.

Cancer Biol Ther 2017 Jul 5;18(7):470-472. Epub 2017 May 5.

a Clinical Pharmacology Program , Office of the Clinical Director, National Cancer Institute, National Institutes of Health , Bethesda , MD , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/15384047.2017.1323600DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5639830PMC
July 2017

Cellular identity crisis: Antiandrogen resistance by lineage plasticity.

Cancer Biol Ther 2017 Nov 5;18(11):841-842. Epub 2017 May 5.

a Clinical Pharmacology Program , Medical Oncology Branch, CCR, NCI/NIH, National Cancer Institute , Bethesda , MD , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/15384047.2017.1323599DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5710664PMC
November 2017

Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study.

J Clin Oncol 2017 Jul 4;35(19):2193-2202. Epub 2017 May 4.

Jung-Min Lee, Cody J. Peer, Alexandra Zimmer, Stanley Lipkowitz, Christina M. Annunziata, Liang Cao, Nicole Houston, Dana-Adriana Botesteanu, Jeffers Nguyen, William D. Figg, and Elise C. Kohn, Center for Cancer Research, National Cancer Institute, Bethesda; Ashley Cimino-Mathews, Janis M. Taube, Elizabeth Thompson, Aleksandra Ogurtsova, and Haiying Xu, The Johns Hopkins Medical Institution, Baltimore; and Tony W. Ho, AstraZeneca, Gaithersburg, MD; and Maria I. Harrell and Elizabeth M. Swisher, University of Washington, Seattle, WA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.72.1340DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5493052PMC
July 2017

A new predictive tool for postoperative radiotherapy in prostate cancer.

Cancer Biol Ther 2017 05 18;18(5):277-278. Epub 2017 Apr 18.

a Center for Cancer Research , National Cancer Institute, National Institutes of Health , Bethesda , MD , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/15384047.2017.1310347DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5499754PMC
May 2017

Piecing the puzzle together: Docetaxel cycles and current considerations in the treatment of metastatic castration-resistant prostate cancer.

Cancer Biol Ther 2017 04 25;18(4):203-204. Epub 2017 Feb 25.

a Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health , Bethesda , MD , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/15384047.2017.1295192DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5450733PMC
April 2017